Reuters logo
BRIEF-BioTime and Processa announce their intention to enter into a HyStem® sublicense for drug delivery
October 11, 2017 / 11:24 AM / in a month

BRIEF-BioTime and Processa announce their intention to enter into a HyStem® sublicense for drug delivery

Oct 11 (Reuters) - BioTime Inc

* BioTime and Processa announce their intention to enter into a HyStem® sublicense for drug delivery

* BioTime - ‍reached agreement to sublicense certain HyStem rights to Processa Pharmaceuticals for creation of sustained-release delivery platform​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below